Apnimed, a late-stage sleep apnea biotech, eyes IPO in the second half

Ap­n­imed, which has a nov­el sleep ap­nea drug in Phase III, is con­sid­er­ing a po­ten­tial IPO in the sec­ond half of this year even as biotech en­tries to Wall Street have start­ed to slow.

The com­pa­ny’s cur­rent­ly talk­ing to bankers, CEO Lar­ry Miller told End­points News in an in­ter­view on Tues­day, and is well po­si­tioned to take ad­van­tage of in­vestor de­mands af­ter one more pri­vate fi­nanc­ing ex­pect­ed in the first half of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.